心肌桥中的抗血小板治疗:来自RIALTO注册表的见解
Renzo Laborante1, Giuseppe Ciliberti1, Gaetano Rizzo2
1Department of Cardiovascular and Thoracic Sciences Catholic University of the Sacred Heart Rome Italy.
Journal of the American Heart Association
|July 4, 2025
概括
抗血小板治疗 (APT) 经常被处方给心肌桥 (MB) 患者. 然而,这项研究发现,单一的APT增加了出血风险,但没有改善MB患者的缺血结局.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
- 临床试验 临床试验
背景情况:
- 心肌桥 (MB) 是冠状动脉常见的一种先天性异常.
- 与MB相关的临床管理和结果是正在进行的研究领域.
- 了解抗血小板治疗 (APT) 在MB患者中的作用对于优化治疗策略至关重要.
研究的目的:
- 在被诊断为心肌桥 (MB) 的患者中研究抗血小板治疗 (APT) 的利用模式.
- 评估单个APT对MB患者缺血和出血事件发生率的影响.
- 评估APT在这个特定患者群体中的安全性和有效性.
主要方法:
- 这项研究利用了来自雄心勃勃的多中心RIALTO注册表 (NCT05111418) 的数据.
- 包括患有MB且没有先前注射APT或抗凝药的患者.
- 患者被分为接受单次APT或不接受APT的组,净不良临床事件作为主要终点.
主要成果:
- 在221名分析的MB患者中,64%接受一次APT.
- 随访时间中位数为1661天,显示单次APT患者的不良临床事件净率显着更高 (aHR,6.2;P=0.03).
- 这种增加的风险主要是由轻微的出血事件 (aHR,10.58;P=0.02) 驱动的,缺血事件没有显著差异.
结论:
- 单抗血小板疗法 (APT) 通常用于心肌桥 (MB) 患者.
- 在MB患者中使用单个APT与出血风险增加有关.
- 目前的证据表明,单个APT对该人群中缺血事件没有明显的益处.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
652
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
652
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
702
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
702
Coronary Artery Disease V: Interprofessional Care
38
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
38
Peripheral Artery Disease III: Interprofessional Care
32
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
32
Angina IV: Management
28
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
28
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41


